Articles & guides — page 10
125 cited, vendor-independent pieces on the questions people actually ask — reconstitution and handling, half-lives, compound comparisons, and how to track a protocol. Research and education only; never dosing advice, never sourcing.
125 articles
What is the difference between compounded and brand GLP-1?
Compounded versus branded GLP-1 products: what compounding means, why the reconstitution math differs, and the real FDA regulatory context. Education only.
Concept / methodTracking & protocols4 minIs compounded semaglutide still legal? (2026 update)
Compounded semaglutide's legal status explained: the FDA drug-shortage exception that allowed it, the 2024–2025 shortage resolutions, and the restricted 2026 picture. Education only.
Concept / methodTracking & protocols5 minAre peptides legal?
Are peptides legal? It depends on which peptide and the context. A plain-English 2026 guide to FDA-approved vs research peptides, compounding, and sport rules. Education only.
Concept / methodTracking & protocols3 minIs BPC-157 legal?
Is BPC-157 legal? A plain-English look at its US status: not FDA-approved, sold "for research", the 503A compounding decision, and the WADA sport ban. Education only.
Concept / methodTracking & protocols4 minPeptide compounding pharmacies, explained
What a peptide compounding pharmacy is, how 503A and 503B compounding differ, and how to tell a legitimate one from the rules alone. Education only, no sourcing.
Concept / methodTracking & protocols3 minWhat is happening with FDA peptide regulation in 2026?
FDA peptide regulation in 2026, explained: the 503A bulk-substances review, the advisory committee, the direction of travel — and how to follow the primary sources yourself. Education only.
Concept / methodTracking & protocols7 minBPC-157 doses: what 182 people actually report
First-party data: 244 structured BPC-157 reports from 182 people — the dose distribution by route, the milligram/microgram collision hiding inside it, stacks, and honest evidence context.
PreclinicalTracking & protocols7 minSS-31 (elamipretide): what the trial found, and what 117 people actually report
First-party data on SS-31 (elamipretide): 197 structured reports from 117 people describing their own use, set against the completed MMPOWER-3 phase 3 trial and the Barth syndrome approval.
Human clinical dataTracking & protocols7 minSLU-PP-332 doses: what 133 people actually report
First-party data: 216 structured SLU-PP-332 reports from 133 people. The community splits almost exactly in half over whether this is a microgram or a milligram compound.
PreclinicalTracking & protocols6 minMOTS-c: what your body makes, what mice did, and what 202 people actually report
First-party data on MOTS-c: 294 structured reports from 202 people describing their own use, set against the human evidence (endogenous levels, measured) and the mouse evidence (injected, per kilogram). No human trial of injected MOTS-c exists.
PreclinicalUsing Zyra Track2 minGetting started with Zyra Track
A first-run walkthrough of Zyra Track: onboarding, what gets set up, and how to log your first dose. Free during the founding period.
Concept / methodUsing Zyra Track2 minHow to log a dose in Zyra Track
How the quick-log flow works in Zyra Track: logging a dose in a few taps, retroactive logging, and how it feeds your Today view and level curves.
Concept / methodZyra Track is a research and educational utility. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of any compound. We never sell or source compounds and refuse sourcing questions. Consult a qualified clinician for decisions about your health.